The Board of Directors of the Issuer looks forward to unveiling the initial results of our clinical trials to a group of leading industry experts and the public at large. The Board of Directors of the Issuer believes that the instrument has the potential to transform an industry that has been plagued with safety concerns with one of the highest rates of malpractice in medicine; and also believes that instrument represents the future of drug delivery.
Legal basis: § 3 subparagraph 1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market"
Źródło:Komunikaty spółek (EBI)